Advanced Renal Cell Carcinoma Completed Phase 3 Trials for Sorafenib (DB00398)

Also known as: Advanced Renal cell carcinoma

IndicationStatusPhase
DBCOND0032596 (Advanced Renal Cell Carcinoma)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01076010An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)Treatment
NCT01030783A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaTreatment